Posted by Michael Wonder on 26 Jul 2019
FDA approves Feraccru with a broad label of treating iron deficiency in adults
26 July 2019 - Feraccru to be marketed as Accrufer in the USA.
Shield Therapeutics announces that the U.S. FDA has approved its lead product Feraccru/Accrufer for the treatment of iron deficiency in adults.
Feraccru is already approved in both the European Union and Switzerland for the treatment of iron deficiency in adults and commercialisation activities in these territories are progressing well via Shield’s licensing partners.
